AbbVie Inc. is 18.8x more valuable than Royalty Pharma plc by market capitalization ($397.44 B vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | ABBV |
|---|---|---|
| Market cap | $21.16 B | $397.44 B |
| US-listed rank | #598 | #28 |
| Revenue (latest FY) | $2.38B | $61.16B |
| Net income (latest FY) | $770.95M | $4.23B |
| Net margin | 32.4% | 6.9% |
| P/E (trailing FY) | 27.4 | 94.0 |
| SEC filings | 588 | 1,008 |
AbbVie Inc. is 18.8x more valuable than Royalty Pharma plc by market capitalization ($397.44 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while AbbVie Inc. reported $61.16B.
Full pages: Royalty Pharma plc and AbbVie Inc., or browse the full rankings.